Get to know our clinical trials

A randomized, open-label phase III clinical trial to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed plus carboplatin or cisplatin in patients with lung cancer.

Imagen del Dr. Miguel Fernández de Sanmamed Gutiérrez, Investigador principal del grupo Onco-Inmunología Aplicada y Traslacional de la Clínica Universidad de Navarra
Dr. Miguel Fernández de Sanmamed Curriculum
Specialist Medical Oncology Department
Navarre headquarters
Cancer Center
Lung Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid

Technical Summary

  • A RANDOMIZED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB AND PEMETREXED PLUS CARBOPLATIN OR CISPLATIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION (KRASCENDO 2).
  • Code EudraCT: 2024-518365-10-00
  • Protocol number: CO45042
  • Promoter: Roche Farma, S.A.
  • Molecule/Drug: Divarasib y pembrolizumab
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION